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Abstract 
Background: Hyperprolactinemia has been associated with changes in body composition and metabolic abnor-
malities. Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. 
This study was designed to assess the anthropometric and metabolic alterations associated with prolactinoma and 
response of these abnormalities to cabergoline treatment.
Methods: In a non-randomised matched prospective design, 19 consecutive patients with prolactinoma (median 
PRL 118.6 (105.3) μg/L) and 20 controls were studied. The controls were age, gender and body mass index (BMI) 
matched. Anthropometric data and metabolic variables were studied at baseline, 3 and 6 months after cabergoline 
treatment.
Results: Patients with prolactinoma had increased level of fasting plasma glucose (P < .001), LDL-cholesterol 
(P = .001) and triglycerides (TG) (P = .009) as compared to age, gender and BMI matched healthy controls. There was 
a significant decrease of body weight at 3 months (P = .029), with a further decline at 6 months (P < .001) of cabergo-
line therapy. In addition, there was a significant decrement of BMI (P < .001), waist circumference (P = .003), waist-hip 
ratio (P = .03) and total body fat (P = .003) at 6 months of cabergoline treatment. A significant decline in plasma 
glucose (P < .001), total cholesterol (P = .009), LDL-cholesterol (P < .001) and TG (P < .001) was seen after 6 months of 
cabergoline treatment.
Conclusions: Patients with prolactinoma have adverse metabolic profile compared with matched controls. Normali-
zation of PRL with cabergoline corrects all the metabolic abnormalities.
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Background
Prolactin (PRL) exerts a wide variety of effects on metab-
olism, in addition to its well-known actions on lacta-
tion and gonadal function [1–4]. Several animal and few 
human studies (especially in men) describe a higher body 
weight in patients with hyperprolactinemia (HPL), the 
exact mechanism of which is not clear [5, 6]. A combi-
nation of factors like decreased dopaminergic tone, low 
adiponectin, hypogonadism with or without associated 
leptin resistance could contribute to weight gain [7–10]. 
Hyperprolactinemia has also been linked to alteration in 
glucose homeostasis, insulin sensitivity and lipid param-
eters. Hyperglycemia with or without insulin resistance 
has been demonstrated in men and women with HPL 
because of its effects on the growth of islet cells and 
insulin production [11, 12]. Many studies have demon-
strated adverse lipid profiles such as increased low-den-
sity lipoprotein (LDL), triglycerides (TG) and decreased 
high-density lipoprotein (HDL) in people with HPL. This 
could be due to a decrease in lipoprotein lipase activity 
in fat cells and subsequent effects on adipose tissue [13]. 
Effects of normalization of PRL [with dopamine agonists 
(DA)] on body weight, glucose and lipid homeostasis is a 
matter of debate and is being explored [14–16]. There is 
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some disagreement on metabolic abnormalities in people 
with HPL and so is its response to treatment with DA. 
Aims of the present research were: (1) to study the meta-
bolic abnormalities in people with prolactinoma com-
pared to healthy age, gender and body mass index (BMI) 
matched controls and (2) the effect of normalization of 




This study was conducted in the Department of Endo-
crinology at a tertiary care hospital in North India over 
a period of 1½ years. Twenty-eight consecutive patients 
with prolactinoma because of PRL secreting pituitary 
adenoma and twenty age, gender and BMI matched 
controls, were included in the study. Out of 28 patients, 
eight women were excluded (four conceived and four 
were lost to follow up). One man with prolactinoma 
and hypogonadism, on testosterone replacement was 
also excluded in the final analysis. Thus, the final sam-
ple consisted of 19 patients (eighteen women and one 
man) and 20 controls. Controls were healthy first or 
2nd degree relatives without any hypertension, diabetes 
and were not any medications. The study was approved 
by the Institutional Ethics Committee and informed 
consent was obtained from all patients and controls. 
Patients with elevated PRL levels on at least two occa-
sions and magnetic resonance imaging (MRI) evidence 
of pituitary adenoma were included. Exclusion criteria 
were secondary causes of HPL, pregnancy or patients 
on medication for dyslipidemia and diabetes mellitus at 
study entry.
Study protocol
Anthropometric and laboratory measurements in cases 
and controls were assessed at baseline. Patients with pro-
lactinoma were reassessed at 3 and 6 months after initia-
tion of cabergoline treatment. Blood samples were taken 
after an overnight fast for measurement of metabolic 
parameters (glucose and lipid profile), and hormones like 
insulin, PRL, thyroid stimulating hormone (TSH), thy-
roxine (T4), testosterone, growth hormone (GH), folli-
cle stimulating hormone (FSH) and luteinizing hormone 
(LH). Insulin resistance was measured by using homeo-
stasis model assessment-insulin resistance (HOMA-IR) 
which is calculated as a product of fasting plasma insu-
lin (mIU/L) and glucose (mmol/l) divided by 22.5. All the 
patients were treated with cabergoline (0.5  mg orally/
week) with dosage titration to normalise serum PRL. 
Serum PRL was measured monthly until normalization. 
During the study period, patients were instructed to 
continue their routine homemade diets and not to curtail 
their routine diet and activity.
Anthropometric data
Both cases and controls were examined by measurement 
of weight and height, using standard measurements. 
BMI was calculated as weight in kgs divided by square 
of height in meters (kg/m2). Measurements of waist and 
hip were taken to calculate waist-hip ratio (WHR). Total 
body fat was measured by dual energy X-ray absorptiom-
etry (DEXA) scan (GE lunar DPX pro) at baseline in both 
cases and controls and after 6  months of cabergoline 
treatment in patients with prolactinoma. Obesity was 
defined as per “Asia-Pacific guidelines of obesity classi-
fication” [17]. BMI of 23–24.9  kg/m2 was considered as 
overweight and ≥25 kg/m2 as obesity.
Biochemical and hormonal assays
Serum PRL was measured using a commercial chemilu-
minescent immunoassay (Beckman Coulter Unicel, DXI) 
normal range: 1–27  μg/L (women); 1–20  μg/L (men). 
TSH, T4, FSH, LH, GH, cortisol and testosterone were 
also measured by using commercial chemiluminescent 
immunoassays (Beckman Coulter Unicel, DXI). Plasma 
glucose was estimated by enzymatic method using glu-
cose oxidase and peroxidase on an automated chemistry 
analyzer (HITACHI-912). Lipid parameters were ana-
lysed with commercially available enzymatic reagents 
(Audit Diagnostics, Ireland) adapted to the Hitachi 912 
autoanalyzer. The upper normal limit for reference pop-
ulation for fasting total cholesterol, LDL, HDL, TG and 
glucose were 5.18, 3.10, 1.8, 2.26 and 5.5 mmol/l respec-
tively. Insulin was measured by immunoradiometric 
assay (Insulin IRMA, Beckman coulter, France) by using 
commercial kits with intra-assay and inter-assay coeffi-
cients of variation, 3.99 and 4.80 % respectively (normal 
reference 20.83–111.12 pmol/l).
Statistical analysis
The statistical software SPSS 20 was used to analyse the 
data. The continuous variables are shown in terms of 
descriptive statistics like mean, SD, median and inter quar-
tile range. The Parametric and non-parametric tests have 
been used to analyse the data after verifying the distribu-
tion of variables with the help of Shapiro–Wilk test. The 
Student’s independent t test and Wilcoxon-Mann–Whit-
ney U test was used to compare the parameters between 
cases and controls at baseline. Also the paired t test and 
Wilcoxon signed rank test has been used to analyze the 
data at baseline and 3 and 6 months of cabergoline treat-
ment. All results have been described on 5 % level of signif-
icance i.e. P value of <.05 being considered as significant.
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Results
Out of 19 patients, 15 had microadenoma and four had 
macroadenoma. Out of 18 women, one had primary 
amenorrhoea, 12 had secondary amenorrhoea and the 
other five were eumenorrheic. Four women had primary 
infertility and two had secondary infertility. Two women 
had primary hypothyroidism and were on adequate doses 
of levothyroxine at the time of entry in the study. Two 
patients with macroprolactinoma had morning cortisol 
<275.9 mmol/l. Insulin tolerance test demonstrated nor-
mal cortisol and GH responses in both of these patients. 
In none of these patients, was there any suggestion of 
extension of pituitary mass into third ventricle on MRI.
Serum PRL normalized in 18 out of 19 patients after 
1  month and in one patient within 6  months of caber-
goline therapy. Median PRL level decreased from 
118.6 μg/L at baseline to 10.4 μg/L at 3 months (P < .001) 
and 9.4 μg/L at 6 months (P < .001).
Metabolic parameters in cases and controls
Out of 19 patients, seven (36.8 %) were obese, four (21 %) 
were overweight and two had impaired fasting glucose. 
Among controls, four (20  %) were obese, four (20  %) 
were overweight and none had impaired fasting glucose. 
Mean (SD) age of patients was 27.3 (6.2) years and BMI 
was 24.2 (4) kg/m2. With cases and controls comparable 
in body weight and BMI, patients with prolactinoma had 
significantly higher trunk fat on DEXA measurement: 
[mean (SD) truncal fat of 11.0 (4.2)  kg in cases and 9.3 
(2.8) kg in controls (P = .044)], though there was no dif-
ference in total body fat. Patients with prolactinoma 
had significantly higher levels of fasting plasma glucose 
compared to controls (4.8  ±  0.5  mmol/l in cases and 
4.2 ± 0.3 mmol/l for controls, P < .001). LDL-cholesterol 
was significantly higher in cases compared to controls 
(2.9 ± 0.8   vs 2.1 ± 0.5 mmol/l, P =  .001). Similarly TG 
were significantly higher in cases compared to controls 
(1.8 ± 0.4 vs 1.4 ± 0.4 mmol/l, P =  .009). HDL-choles-
terol in cases tended to be lower than that of controls but 
did not achieve statistical significance (Table 1).
Metabolic parameters before and after cabergoline 
treatment
The prevalence of obesity decreased from 36.8  % at 
baseline to 21  % at 6  months after cabergoline treat-
ment. There was a significant decline in mean (SD) body 
weight from 57.3 (9.5) kg at baseline to 54.8 (9.2) kg after 
6  months (P  <  .001). Similarly, there was a significant 
decrease in mean (SD) BMI from 24.2 (4.0) kg/m2 at base-
line to 23.2 (3.9) kg/m2 (P < .001) after 6 months of caber-
goline treatment. There was a significant decrease in 
fasting plasma glucose from 4.8 ± 0.5–4.3 ± 0.3 mmol/l, 
LDL-cholesterol from 2.8  ±  0.9–2.0  ±  0.3  mmol/l and 
TG from 1.8  ±  0.4–1.2  ±  0.2  mmol/l after 6  months 
(P < .001 for all). Similarly, a trend was seen in total cho-
lesterol levels falling from 4.5 ±  1.0  mmol/l at baseline 
to 3.6 ±  0.5 mmol/l (P =  .009) after 6 months of treat-
ment (Table  2). Two patients had impaired fasting glu-
cose, which normalized after treatment. There was a 
trend towards an increase in insulin sensitivity, as is evi-
dent from a decrease in plasma glucose and HOMA-IR, 
after achievement of normoprolactinemia at 6 months of 
treatment (Table 2). After 6 months of cabergoline treat-
ment, LDL- cholesterol decreased to a level comparable 
to controls whereas TG and plasma glucose showed a 
further decline.
Hormonal profile of cases and controls
Mean estradiol at baseline in patients with prolacti-
noma was significantly lower as compared to controls 
(52.7  ±  24.3  pg/ml in cases and 85.7  ±  42.6  pg/ml for 
controls, P =  .018) and it increased to 87.7 ±  54.5  pg/
ml after 3  months (P  =  .004) without any further sig-
nificant increase after 6 months of cabergoline treatment 
(P = 0.12). Concentrations of FSH and LH were in nor-
mal range both at beginning and at the end of treatment.
To understand whether the improvement in meta-
bolic parameters was because of a decrease in weight 
Table 1 Baseline characteristics of cases and controls
HOMA-IR homeostatic model of insulin resistance, LDL low density lipoprotein 
cholesterol, HDL high density lipoprotein cholesterol
a Normally distributed data are expressed as mean (SD). Other data (non-
normally distributed) expressed as median (interquartile range)
Parameter Cases (n = 19) Controls (n = 20) P value
Agea 27.3 (6.2) 27.1 (5.6) .9
Gender (men:women) 1:18 2:18
Body weight (kg)a 57.3 (9.5) 60.3 (11.1) .35
BMI (kg/m2)a 24.2 (4.0) 24.6 (3.9) .73
Waist (cm)a 85.3 (12.0) 83.3 (7.4) .52
Hip (cm)a 91.1 (8.7) 91.4 (9.0) .91
Waist–hip ratioa 0.94 (0.12) 0.92 (0.09) .68
Body fat (kg) 23.4 (10.4) 20.5 (8.3) .69
Trunk fat (kg)a 11.0 (4.2) 9.3 (2.8) .044
Fasting glucose (mmol/l)a 4.8 (0.5) 4.2 (0.3) <.001
Fasting insulin (pmol/l) 34.3 (54.6) 35.9 (22.3) .82
HOMA-IR 1.1 (1.27) 1.4 (0.59) .64
Total cholesterol (mmol/l) 4.5 (1.4) 3.4 (1.6) .02
LDL (mmol/l)a 2.9 (0.8) 2.1 (0.5) .001
HDL (mmol/l) 1.1 (0.3) 1.2 (0.3) .04
Triglycerides (mmol/l)a 1.8 (0.4) 1.4 (0.4) .009
Uric acid (µmol/l)a 297.9 (66.6) 206.9 (75.5) <.001
FSH (IU/l)a 5.7 (2.6) 5.8 (1.8) .88
LH (IU/l)a 5.3 (4.4) 5.2 (1.5) .96
Estradiol (pg/ml)a 52.7 (24.3) 85.7 (42.6) .018
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after cabergoline treatment, patients were sub grouped 
into two categories, one with a decrease and another 
without change in BMI after cabergoline treatment. We 
found that there was significant change in fasting plasma 
glucose, LDL-cholesterol and TG at 3 and 6  months of 
cabergoline therapy in both the groups.
Discussion
The metabolic consequences of HPL are being explored. 
HPL has been found to be associated with increased food 
intake and weight gain which promotes obesity [5, 7]. In 
line with the hypothesis of a pivotal role of dopaminergic 
tone in regulating body weight, the decrease in BMI and 
body fat content following PRL normalization in hyper-
prolactinemic patients receiving treatment with caber-
goline has been ascribed to type 2 dopamine receptor 
activation [18].
Metabolic abnormalities in prolactinoma
Many metabolic abnormalities have been described in 
men and women with HPL. Patients with HPL have 
insulin resistance and glucose intolerance compared 
to normal individuals [19, 20]. In the present study, we 
documented higher levels of fasting plasma glucose in 
patients with prolactinoma compared to age, gender and 
weight matched controls. Many previous case control 
studies have documented higher insulin resistance and 
abnormal glucose tolerance in patients with prolacti-
noma compared to healthy controls [21–24]. In the pre-
sent study, fasting plasma insulin and glucose were high 
in patients with prolactinoma compared to age, gender 
and BMI matched healthy controls implying that dia-
betogenic effect of HPL may be independent of gender 
and body weight. We documented increased levels of 
LDL-cholesterol and TG in patients with prolactinoma 
compared to age, gender and BMI matched healthy con-
trols. We also documented high total cholesterol and 
low HDL in patients with prolactinoma compared to 
controls but the difference was not statistically signifi-
cant. The association between HPL and hyperlipidemia 
(especially increased total cholesterol and TG) has been 
documented as early as 1982 in a case control study [25]. 
In a subsequent case control study, low HDL-cholesterol 
has been documented though there was no difference in 
serum TG and LDL-cholesterol [26]. In another study, 
total cholesterol and LDL-cholesterol concentration was 
found to be higher in women with hyperprolactinemic 
amenorrhea compared to age matched controls [27]. The 
abnormal lipid profile in people with HPL is contributed 
partly by increase in body weight and partly because of 
the lipogenic action of PRL [28]. Taking a BMI matched 
control population; we did not demonstrate any increase 
in body fat on DEXA, though trunk fat was significantly 
higher in patients with prolactinoma. There is a limited 
data on body fat distribution in patients with HPL. Some 
studies have revealed a high body fat mass in patients 
with HPL [21]. Patients with HPL had lower estradiol 
concentrations as compared to that of controls, which is 
related to hypogonadism.
Effect of normalization of prolactin with cabergoline 
on metabolic parameters
In patients with HPL, the effect of DA treatment on body 
weight and other metabolic parameters is a subject of 
active research. Some, but not all the studies have doc-
umented reduction in body weight and BMI in patients 
with prolactinoma after treatment with DA [19–23]. The 
effect of DA treatment on weight seems to have gender 
difference. A recent study has shown that reduction in 
body weight and BMI after DA treatment is seen only in 
men [24], while another study revealed major reduction 
Table 2 Anthropometric and  hormonal profile of  patients 
at diagnosis and after 3 and 6 months on cabergolin treat-
ment
HOMA-IR homeostatic model of insulin resistance
Baseline compared with * 3 months and † 6 months after cabergolin treatment
a Normally distributed data are shown as mean (SD). Other data (non-normally 
distributed) are expressed as median (interquartile range)
Parameter Baseline Cabergoline treatment P value
3 months 6 months * †
Body weight 
(kg)a
57.3 (9.5) 56.6 (9.1) 54.8 (9.2) .029 <.001
BMI (kg/m2)a 24.2 (4.0) 23.9 (4.2) 23.2 (3.9) .09 <.001
Waist (cm)a 85.3 (12.0) 84.9 (11.3) 82.3 (10.0) .30 .003
Waist-hip ratioa 0.9 (0.06) 0.9 (0.06) 0.9 (0.07) .89 .039
Body fat (kg) 23.4. (10.4) – 22.3 (11.8) – <.001
PRL (µg/L) 118.6 (105.3) 10.45 (20.0) 9.4 (5.9) <.001 <.001
TSH (U/L)a 3.4 (1.7) 3.7 (2.0) 4.3 (1.3) .60 .09
T4 (nmol/l)a 110.5 (25.2) 125.3 (33.9) 114.4 (22) .10 .60
Fasting glucose 
(mmol/l)a
4.8 (0.5) 4.6 (0.4) 4.3 (0.3) .006 <.001
Fasting insulin 
(pmol/L)
34.3 (54.6) 37.6 (43.3) 32.2 (20.9) .62 .24
HOMA-IR 1.1 0 (1.27) 1.21 (1.10) 1.04 (0.52) .71 .064
Total cholesterol 
(mmol/l)a
4.5 (1.0) 4.1 (0.8) 3.6 (0.5) .11 .009
LDL-cholesterol 
(mmol/l)
2.8 (0.9) 2.3 (0.5) 2.0 (0.3) .01 <.001
HDL-cholesterol 
(mmol/l)
1.1 (0.3) 1.0 (0.2) 1.1 (0.2) .36 .32
Triglycerides 
(mmol/l)a
1.8 (0.4) 1.3 (0.4) 1.2 (0.2) .004 <.001
FSH (IU/l) 6.0 (3.8) 5.6 (4.0) 5.6 (3.2) .87 1.00
LH (IU/l) 5.1 (7.4) 5.23 (2.7) 5.3 (1.3) .62 .54
Estradiol (pg/
ml)a
52.7 (24.3) 87.7 (54.5) 63.4 (167.4) .004 .12
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in body weight and BMI in men as compared to women 
[7]. In the present study, we documented significant 
reduction in body weight after 3  months with a further 
decline after 6 months of cabergoline treatment. We also 
documented significant reduction in BMI, WHR and 
body fat after 6  months of cabergoline treatment. Our 
study population predominantly involved women; there-
fore, the beneficial effects of DA treatment on weight 
may not be restricted to men only. HPL of any etiology 
has been found to be associated with weight gain [24, 29, 
30]. Weight gain associated with HPL is believed to be 
because of changes in the appetite and satiety regulating 
systems [31, 32]. Dopamine agonists have been found to 
induce weight loss [31–34]. The improvement in weight 
and abdominal obesity after DA treatment may appear as 
early as 3 months as seen in the present study and per-
sist even up to 5 years [24, 29]. We documented signifi-
cant reduction of fasting plasma glucose after 3 months 
of cabergoline treatment with a further decline after 
6 months of treatment.
There is recent evidence that insulin sensitivity 
improves after 6 months of cabergoline treatment as doc-
umented by improvement in HOMA-IR [26, 27]. In the 
present study, we documented improvement in HOMA-
IR after 6  months of cabergoline treatment. Numerous 
studies have demonstrated an improvement in insulin 
sensitivity with DA in patients with HPL and changes are 
independent of variation in body weight [21, 23, 27, 35]. 
Though some short-term studies involving treatment of 
HPL with DA up to 12 weeks did not reveal any changes 
in insulin resistance and blood glucose [20], many stud-
ies have demonstrated significant improvement in insulin 
resistance after 6 months to 5 years of DA treatment. In 
addition, significant improvement in insulin sensitivity is 
documented in adult obese individuals without HPL after 
treatment with bromocriptine [36].
In the present study, we documented significant reduc-
tion of LDL-cholesterol and TG after 3 months of caber-
goline treatment with a further decline at 6  months. 
We also documented significant reduction of total cho-
lesterol after 6  months (but not at 3  months) of treat-
ment. Many studies have shown improvement in lipid 
profile after treatment with DA. The improvement seen 
can be as early as 2  months and up to 5  years of treat-
ment [19, 31, 35]. The changes in lipid parameters are 
seen well before the changes in the body weight suggest-
ing that improvement may be because of direct effect of 
DA and not related to weight. Also, in the present study, 
there was a significant decrease in plasma glucose, LDL 
and TG after 3 and 6 months after treatment with caber-
goline, independent of change in body weight. Treat-
ment with bromocriptine has been shown to decrease 
total cholesterol in obese non-diabetic hyperinsulinemic 
women [37]. Continued improvement in lipid parameters 
has also been shown with higher doses of cabergoline 
even after 12  months of treatment [38]. In the present 
study, after completion of 6 months of cabergoline treat-
ment, fasting plasma glucose, LDL-cholesterol and TG 
in cases were similar to that of controls indicating rever-
sal of these metabolic abnormalities. The fall in TG and 
plasma glucose was well below the level seen in age and 
BMI matched controls suggesting that cabergoline may 
have a role in decreasing TG beyond PRL decreasing 
effect. After 3  months of cabergoline treatment, there 
was a significant increase in estradiol as compared to 
baseline without any further increase after 6 months.
Limitations of the study
Two important limitations of the present study include 
small sample size and short follow-up.
Further studies with a larger cohort and longer dura-
tion of follow-up are required, perhaps including long-
term cardiovascular outcomes as well.
Conclusion
The current study demonstrated that, patients with pro-
lactinoma have metabolic abnormalities like increased 
truncal fat and high levels of plasma glucose, LDL-cho-
lesterol, TG and lower levels of estradiol compared to 
healthy controls. We demonstrated a significant reduc-
tion of body weight, BMI, waist, WHR, total body fat, 
fasting plasma glucose, total cholesterol, LDL-choles-
terol, TG with a significant increase in estradiol after 
treatment with cabergoline, with total cholesterol and 
TG decreasing to lower levels compared to matched 
healthy controls. Insulin sensitivity improved but did 
not achieve a statistical significance. We suggest that it 
is important to consider the metabolic profile of patients 
with prolactinoma before a decision to stop DA treat-
ment is taken.
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